REGEN-COV (casirivimab and imdevimab)

URI: https://gptkb.org/entity/REGEN-COV_(casirivimab_and_imdevimab)
GPTKB entity
Statements (40)
Predicate Object
gptkbp:instanceOf gptkb:COVID-19
gptkb:monoclonal_antibody_combination
gptkbp:administeredBy saline solution
gptkbp:approvedBy gptkb:EMA_(conditional_approval)
gptkb:FDA_(Emergency_Use_Authorization)
2020
gptkbp:ATCCode gptkb:J06BD08
gptkbp:brand gptkb:Ronapreve
gptkb:REGEN-COV
gptkbp:CASNumber 2421380-07-0 (casirivimab)
2421380-08-1 (imdevimab)
gptkbp:contraindication known hypersensitivity to components
gptkbp:developedBy gptkb:Regeneron_Pharmaceuticals
gptkb:Roche
gptkbp:effect reduced with Omicron variant
gptkbp:EUARevoked 2022 (in the US)
gptkbp:form solution for injection
gptkbp:halfLife ~25-30 days
gptkbp:hasComponent gptkb:casirivimab
gptkb:imdevimab
gptkbp:indication treatment of COVID-19
post-exposure prophylaxis of COVID-19
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction neutralizes SARS-CoV-2 spike protein
gptkbp:monoclonalAntibodyType gptkb:IgG1
gptkbp:pregnancyCategory not assigned
gptkbp:routeOfAdministration subcutaneous
intravenous
gptkbp:sideEffect nausea
pruritus
rash
allergic reactions
infusion-related reactions
gptkbp:storage 2–8°C
gptkbp:target gptkb:SARS-CoV-2_spike_protein
gptkbp:usedDuringPandemic gptkb:COVID-19_pandemic
gptkbp:WHOModelListOfEssentialMedicines no
gptkbp:bfsParent gptkb:Regeneron_Pharmaceuticals
gptkbp:bfsLayer 6
https://www.w3.org/2000/01/rdf-schema#label REGEN-COV (casirivimab and imdevimab)